bluebird bio Reports Third Quarter 2024 Results and Highlights ...
1 hour ago · - 74 patient starts completed or scheduled to date in 2024 across bluebird’s commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET -
Exploring bluebird bio's Earnings Expectations - Benzinga
22 hours ago · Shares of bluebird bio were trading at $0.3906 as of November 12. Over the last 52-week period, shares are down 86.25%. Given that these returns are generally negative, long-term shareholders are ...
bluebird bio Adjourns Meeting of Stockholders and Announces …
Nov 6, 2024 · bluebird bio also announced today that it will host a conference call to discuss third quarter 2024 results and business updates on Thursday, November 14, 2024 at 8:00 a.m. ET. To access the live ...
Bluebird Bio’s Key Decisions and Shareholder Engagement in 2024
Nov 6, 2024 · Bluebird Bio ( ) has issued an announcement. At bluebird bio, Inc.’s 2024 Annual Meeting, key decisions included increasing the shares under the Incentive Award Plan, electing new board members ...
The latest Bluebirds news from Cardiff City Stadium
5 days ago · Omer Riza has held talks with Jamilu Collins and urged him to be patient after his recent omissions from match-day squads. Collins has fallen behind both Callum O'Dowda and Joel Bagan in the left ...
bluebird bio Reports Second Quarter 2024 Results and Highlights ...
SOMERVILLE, Mass., August 14, 2024 -- (BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported second quarter results and business highlights for the...
press releases - bluebird bio, Inc.
Oct 4, 2024 · SOMERVILLE, Mass. -- (BUSINESS WIRE)--Nov. 5, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia. 10/04/24.
Bluebird’s Plans to Win in Sickle Cell Come Into Focus
Jan 4, 2024 · Bluebird Bio is showing Wall Street it’s ready to compete for sickle-cell patients. The Somerville, Mass.-based biotech said it secured its second outcomes-based agreement with a large national...
bluebird bio Announces FDA Approval of LYFGENIA ...
Dec 8, 2023 · Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies ...
First Patient Begins Newly Approved Sickle Cell Gene Therapy
May 6, 2024 · Kendric Cromer, 12, the first commercial patient for Bluebird Bio’s gene therapy to cure his sickle cell disease, in the hospital as his bone marrow stem cells were being removed for gene editing.